An observational study in Li-Fraumeni Syndrome, Neoplasms and Tp53 Mutations, sponsored by National Cancer Institute (NCI). Recruiting at 2 sites in United States. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by National Cancer Institute (NCI) · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 14 studies in Li-Fraumeni Syndrome with a site in United States — 8 open to participants now, 9 under way, none of them phase 3. Li-Fraumeni Syndrome · United States.
Among the 14 studies in Li-Fraumeni Syndrome with a site in United States, this one has the largest planned enrollment of the 12 observational ones that give a count, is one of 2 that started in 2012, is one of 12 observational ones, and was the 4th registered.
25 studies on the registry are indexed under Li-Fraumeni Syndrome; 16 are open to participants now.
Browse Li-Fraumeni Syndrome studies →8 of the 14 studies in Li-Fraumeni Syndrome with a site in United States are open now. Recruiting first, the newest first:
Sir Mortimer B. Davis - Jewish General Hospital · Sites in United States, Australia, Belgium and 5 more countries
Ages 18–90 · Women only
M.D. Anderson Cancer Center · Sites in United States
Dana-Farber Cancer Institute · Sites in United States
Abramson Cancer Center at Penn Medicine · Sites in United States
Healthy volunteers
St. Jude Children's Research Hospital · Sites in United States
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 13 Li-Fraumeni Syndrome studies recruiting now, 9 (69%) set no upper age limit and 1 (8%) stops at 75 or younger; 9 take children under 18; 5 take healthy volunteers.
This study: all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
14 studies; the count open now beside each. This study's row is marked.
First in 2002; this study’s year is marked. 2 started in 2012.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 5,000 is above the median of 439 across 18 observational studies indexed under Li-Fraumeni Syndrome.
Median enrollment 88 across the 2 interventional studies, 750 across the 12 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
None of the 14 has an industry lead sponsor. The 8 most frequent:
National Cancer Institute (NCI) is the lead sponsor of 3,557 studies on the registry; 336 are open to participants now.
Of its 412 completed or terminated interventional studies of FDA-regulated products, 374 (91%) have results posted.
National Cancer Institute (NCI) has 5 studies filed under Li-Fraumeni Syndrome — fewer than ten, so there is no comparison to draw.
2 of the studies in Li-Fraumeni Syndrome with a site in United States that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06888388Sir Mortimer B. Davis - Jewish General HospitalLong-term Safety of Nipple Sparing Mastectomy in Women With High Penetrance Breast Cancer Susceptibility Genes in Breast Cancer | 2027-02-01 |
| NCT05126810M.D. Anderson Cancer CenterWillingness to Participate in a Trial Comparing Standard Genetic Counseling Versus Personalized Genetic Counseling | 2027-02-02 |
Add all 2 to your calendar (.ics) → With an account.
Among the 14 studies in Li-Fraumeni Syndrome with a site in United States, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Background:
- Li-Fraumeni syndrome (LFS) is a genetic condition that increases the risk for some types of cancer. LFS may lead to cancer of the bone or connective tissue, breast, and brain. It may also increase the risk for certain types of leukemia and other cancers. The only known cause of LFS is a change (called a mutation ) in a gene known as TP53. However, not all people with LFS have a TP53 mutation. Researchers want to study other possible genetic causes of LFS, and factors that may increase or decrease cancer risk in people with the syndrome.
Objectives:
Eligibility:
Design:
Study Description:
This is a natural history study involving questionnaires, clinical and research evaluations, clinical and research laboratory tests, review of
medical records, and cancer surveillance. This is a prospective long-term study of individuals at high risk of cancer due to Li-Fraumeni Syndrome (LFS) or Li-Fraumeni-Like Syndrome (LFL), using a cohort approach. Enrollees are invited to participate in all aspects of the study but can choose to opt out of specific part(s).
Objectives:
Primary Objectives:
these high-risk individuals
Secondary Objectives:
-To evaluate specific tumor characteristics, including histologies (e.g., leukemia types, brain tumor types, etc.) of cancers
diagnosed in individuals with LFS or LFL.
-To evaluate the potential effect of therapeutic radiation and radiation exposure from diagnostic/screening imaging studies on
cancer risk.
Endpoints: Primary Endpoint:
-Occurrence of cancer in individuals and families with LFS or LFL
Eligibility for the LFS study population: - A family or personal medical history of cancers consistent with the diagnosis of LFS or LFL; or, - A personal history of a germline TP53 mutation; or, - A first- or second- degree relative of a TP53 mutation carrier, regardless of mutation status; or, - A personal history of three or more LFS-related primary cancers; or, - A personal history of adrenal cortical carcinoma or choroid plexus carcinoma at any age
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
because of either:
Personal and family medical history must be verified through questionnaires, interviews, review
of medical records and/or review of pathology slides.
There are 72 families who have previously enrolled in the pilot study under protocol 78-C-0039.
As the eligibility criteria remain the same, these families will be eligible for this protocol and will be invited to sign the new consent.
-Ability of subject or Legally Authorized Representative (LAR) to understand and the willingness to sign a written document.
For both the Field and Clinical Center Cohort, the PI will ensure that study investigators will
identify an appropriate LAR consistent with requirements of Policy 403 and will obtain consent
from the LAR as outlined in the consent process before initiating research interventions.
-Pregnant women
In order to study the lifetime rates of cancer development in all individuals with Li-Fraumeni
syndrome, we will need to evaluate what effect pregnancy may have on rate of cancer
development both in affected individuals and unaffected family controls. Additionally, some
cancers are known to have an increased risk of development in the context of pregnancy and
lactation. Exclusion of pregnant women would preclude understanding of these cancer risks for
an important subset of the population.
Pregnant women are eligible for enrollment on the data collection component of this study.
Pregnant women will be included in this study as several endpoints may be assessed during
pregnancy; counseling, education, and other minimal risk procedures (i.e. blood draw) may be
done. We will postpone full clinical evaluations at the Clinical Center of pregnant women until
the subject has recovered post-partum.
All screening studies, for women who are pregnant, or breastfeeding will be deferred while the
woman is pregnant or breastfeeding. Pregnancy testing will be performed for females of childbearing age prior to imaging studies, and the test results must be negative prior to the scan..
The risk to the fetus and pregnant woman would be no greater than minimal for procedures that
are performed.
EXCLUSION CRITERIA:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Patients within a family with a known TP53 mutation who are positive for that mutation.
Patients within a family with a known TP53 mutation who are negative for that mutation.
Unaffected family members.
Patients who meet clinical LFS criteria but haven't had TP53 testing.
Patients within a family with an negative/unknown TP53 mutation.
Prevalence
Learn more about the types of cancers that occur in individuals with LFS and the age at which these cancers are usually found
Time frame: ongoing
Multiple measures
Explore ways to lower cancer risk
Time frame: ongoing
Multiple measures
Explore the typical features of the cancers diagnosed in individuals with LFS
Time frame: ongoing
Multiple measures
Explore the psychological and social functioning issues faced by LFS families
Time frame: ongoing
Multiple measures
Explore the best ways to look for cancers early in individuals with LFS
Time frame: ongoing
Multiple measures
Determine if there is any connection between specific mutations in the TP53 gene and the risk of certain type of cancers
Time frame: ongoing
Multiple measures
Determine if there are any environmental factors or other genes that can change a person's cancer risk associated with LFS
Time frame: ongoing
Multiple measures
Determine how often a change (mutation) in the TP53 gene is found in families in which LFS is suspected
Time frame: ongoing
Started Jan 2012 (actual).
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
National Cancer Institute (NCI) →